Lipoprotein lipase S447X variant associated with VLDL, LDL and HDL diameter clustering in the MetS.

Citation data:

Lipids in health and disease, ISSN: 1476-511X, Vol: 10, Issue: 1, Page: 143

Publication Year:
2011
Usage 88
Abstract Views 43
Downloads 36
Full Text Views 9
Captures 22
Readers 21
Exports-Saves 1
Citations 6
Citation Indexes 6
Repository URL:
https://digitalcommons.wustl.edu/open_access_pubs/409
PMID:
21854610
DOI:
10.1186/1476-511x-10-143
PMCID:
PMC3180704
Author(s):
Wood, Alexis C; Glasser, Stephen; Garvey, W Timothy; Kabagambe, Edmond K; Borecki, Ingrid B; Tiwari, Hemant K; Tsai, Michael Y; Hopkins, Paul N; Ordovas, Jose M; Arnett, Donna K
Publisher(s):
Springer Nature
Tags:
Medicine; Biochemistry, Genetics and Molecular Biology
article description
Previous analysis clustered 1,238 individuals from the general population Genetics of Lipid Lowering Drugs Network (GOLDN) study by the size of their fasting very low-density, low-density and high-density lipoproteins (VLDL, LDL, HDL) using latent class analysis. From two of the eight identified groups (N = 251), ~75% of individuals met Adult Treatment Panel III criteria for the metabolic syndrome (MetS). Both showed small LDL diameter (mean = 19.9 nm); however, group 1 (N = 200) had medium VLDL diameter (mean = 53.1 nm) while group 2 had very large VLDL diameter (mean = 65.74 nm). Group 2 additionally showed significantly more insulin resistance (IR), and accompanying higher waist circumference and fasting glucose and triglycerides (all P < .01). Since lipoprotein lipase hydrolyzes triglyceride in the VLDL-LDL cascade, we examined whether these two patterns of lipoprotein diameter were associated with differences across two lipoprotein lipase (LPL) gene variants: D9N (rs1801177) and S447X (rs328).